Tumors and TDLNs were sampled after mice received one-third of the treatment schedule (i.e., two doses of IL-2/CD40; Figure 5A), to enable identification of tumors responding to treatment and still have enough tumor sample to collect for analysis, as young mice given the full regimen demonstrate complete resolution of tumors which therefore cannot be sampled (26, 29, 30). This evidence concerns the gene CD40 and neoplasm.